Svensson Johan, Ericsson Ulla-Britt, Nilsson Paul, Olsson Catherine, Jonsson Björn, Lindberg Bengt, Ivarsson Sten-A
Department of Pediatrics, Malmö University Hospital, Lund University, SE-205 02 Malmö, Sweden.
J Clin Endocrinol Metab. 2006 May;91(5):1729-34. doi: 10.1210/jc.2005-2400. Epub 2006 Feb 28.
The use of levothyroxine to reduce thyroid size in pediatric patients with goiter due to chronic autoimmune thyroiditis (AIT) remains controversial. In overtly hypothyroid patients, reductions in thyroid volume have been reported, whereas the effect in subclinically hypothyroid and euthyroid patients is less clear.
The objective of the study was to evaluate the effect of levothyroxine treatment on thyroid size (determined with thyroid ultrasonography) in children and adolescents with AIT.
This study included patients with AIT treated at a university hospital outpatient clinic between 1987 and 2004.
Ninety children with AIT (73 girls and 17 boys, aged 6.1-17.7 yr) were included in the study.
Intervention was treatment with levothyroxine for a median 2.8 yr (range 0.5-10.2).
Change in thyroid volume sd score (SDS) during the study period was measured.
Median thyroid volume SDS was reduced in patients euthyroid (-0.4 SDS, P < 0.001), subclinically hypothyroid (-1.4 SDS, P < 0.001), and overtly hypothyroid (-1.8 SDS, P < 0.002) at diagnosis of AIT. Both hypothyroid and euthyroid patients with goiter (thyroid volume > 2.0 SDS) at baseline reduced their median thyroid volume SDS (-1.6 and -0.9, respectively, P < 0.001). Hypothyroid patients without goiter also reduced median thyroid volume SDS (-1.2, P < 0.004), whereas no change was noticed in euthyroid children without goiter.
Levothyroxine treatment is effective in reducing thyroid volume in pediatric patients and is suggested in treatment of goiter caused by AIT, especially in cases of hypothyroid, but also in euthyroid children.
对于因慢性自身免疫性甲状腺炎(AIT)导致甲状腺肿大的儿科患者,使用左甲状腺素减少甲状腺大小仍存在争议。在明显甲状腺功能减退的患者中,已有甲状腺体积减小的报道,而在亚临床甲状腺功能减退和甲状腺功能正常的患者中,其效果尚不清楚。
本研究的目的是评估左甲状腺素治疗对患有AIT的儿童和青少年甲状腺大小(通过甲状腺超声测定)的影响。
本研究纳入了1987年至2004年在大学医院门诊接受治疗的AIT患者。
90名患有AIT的儿童(73名女孩和17名男孩,年龄6.1 - 17.7岁)被纳入研究。
干预措施为使用左甲状腺素治疗,中位治疗时间为2.8年(范围0.5 - 10.2年)。
测量研究期间甲状腺体积标准差评分(SDS)的变化。
在AIT诊断时,甲状腺功能正常的患者(-0.4 SDS,P < 0.001)、亚临床甲状腺功能减退的患者(-1.4 SDS,P < 0.001)和明显甲状腺功能减退的患者(-1.8 SDS,P < 0.002)的甲状腺体积SDS中位数均降低。基线时患有甲状腺肿大(甲状腺体积> 2.0 SDS)的甲状腺功能减退和甲状腺功能正常的患者,其甲状腺体积SDS中位数均降低(分别为-1.6和-0.9,P < 0.001)。无甲状腺肿大的甲状腺功能减退患者的甲状腺体积SDS中位数也降低(-1.2,P < 0.004),而无甲状腺肿大的甲状腺功能正常儿童未观察到变化。
左甲状腺素治疗对减少儿科患者的甲状腺体积有效,建议用于治疗由AIT引起的甲状腺肿大,特别是在甲状腺功能减退的情况下,也适用于甲状腺功能正常的儿童。